Opko Health (OPK) Stock
Diversified healthcare company developing medicines and diagnostic tests. Here's the price, business snapshot, and what's worth knowing about Opko Health in October 2026.
Opko Health, Inc. (OPK) is a diversified healthcare company operating across pharmaceuticals and diagnostics. It develops and commercialises therapeutics while also offering clinical laboratory services and diagnostic products. For investors, key points are its reliance on a mix of product revenues, diagnostic testing income and potential milestone or licensing payments tied to its pipeline and partnerships. Like many small‑cap healthcare companies, Opko’s outlook is shaped by clinical trial progress, regulatory decisions and competitive dynamics. Financial performance can be volatile and the company may require additional capital, which can dilute shareholders. Investors should weigh the potential upside from successful drug or diagnostic launches against patent, regulatory and execution risks. This summary is for general educational purposes only and is not personalised investment advice; investors should consider their objectives and consult a qualified financial adviser before acting.
Opko Health (OPK) Stock Forecast
Analyst price target, next 12 months
$4.20
+157.9% vs today's $1.63
Price range over the last 12 months
Close to its 12-month high
Analysts covering Opko Health have a consensus 12-month target of $4.20, above the current price of $1.63.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying OPKO Health's stock with a target price of $4.20, indicating strong growth potential.
Financial Health
OPKO Health is generating moderate revenue and cash flow, but its profitability is limited.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Milestones Ahead
Clinical and regulatory milestones can materially affect value, offering upside if successful — though outcomes are uncertain and timing can vary.
Diagnostics Revenue Stream
Diagnostic testing and lab services provide recurring revenue diversity, but volumes can fluctuate with market demand and reimbursement changes.
Capital & Dilution
Small‑cap healthcare firms may need additional funding to advance programmes, which can dilute shareholders; review the balance sheet carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
